Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative Colitis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2017
Price :
$35
*
At a glance
- Drugs Baminercept (Primary)
- Indications Ulcerative colitis
- Focus Pharmacogenomic; Therapeutic Use
- 28 Apr 2012 Actual initiation date changed from 20 Jan 2011 to 23 Dec 2010 and additional trial location (Belgium) added as reported by European Clinical Trials Database.
- 09 Jun 2011 New trial record